GAM Holding’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

GAM Holding’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25,146	Closed	-$764K	–	272
2022 Q2	$764K	Hold	25,146	–	–	0.05%	193
2022 Q1	$824K	Hold	25,146	–	–	0.04%	208
2021 Q4	$663K	Sell	25,146 -1,813	-7%	-$140K	0.03%	221
2021 Q3	$2.71M	Hold	26,959	–	–	0.13%	160
2021 Q2	$3.82M	Sell	26,959 -4,141	-13%	-$468K	0.17%	146
2021 Q1	$3.1M	Buy	+31,100	New	+$3.63M	0.14%	168
2020 Q4	–	Sell	-66,750	Closed	-$6.5M	–	347
2020 Q3	$6.5M	Hold	66,750	–	–	0.39%	79
2020 Q2	$10.4M	Hold	66,750	–	–	0.65%	34
2020 Q1	$9.63M	Sell	66,750 -4,500	-6%	-$869K	0.65%	35
2019 Q4	$14.6M	Sell	71,250 -19,800	-22%	-$3.61M	0.69%	32
2019 Q3	$7.31M	Hold	91,050	–	–	0.32%	82
2019 Q2	$8.59M	Hold	91,050	–	–	0.34%	71
2019 Q1	$7.78M	Buy	91,050 +35,650	+64%	+$2.96M	0.33%	81
2018 Q4	$3.11M	Buy	55,400 +800	+1%	+$48.8K	0.16%	152
2018 Q3	$4.46M	Buy	54,600 +8,500	+18%	+$599K	0.16%	158
2018 Q2	$1.61M	Buy	+46,100	New	+$1.4M	0.06%	333

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAM Holding's RETA Position: Q3 2022 in Review

GAM Holding sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 25,146 shares — an estimated $764K sold.

GAM Holding first reported a position in RETA in Q2 2018 and held it in 16 quarters. The position peaked at $14.6M in Q4 2019. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

GAM Holding reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
GAM Holding sold 25,146 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $764K.
GAM Holding first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 16 quarters.
GAM Holding's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $14.6M in Q4 2019.
159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on GAM Holding's 13F filing for Q3 2022, filed 19 Oct 2022.